Mounjaro

Zepbound, Mounjaro Maker Eli Lilly Climbs In Wednesday Pre-Market As Impressive 51% YTD Gain Sparks Stock Split Speculation
Eli Lilly Q3 Earnings On Deck: Stock Split Rumors Heat Up With Weight Loss Gains (CORRECTED)
Eli Lilly Aims To Expand Weight-Loss Drug Trials To Those At Risk, Not Just Overweight
Eli Lilly Q3 Earnings On Deck: Stock Split Rumors Heat Up With Weight Loss Gains (CORRECTED)
Eli Lilly Aims To Expand Weight-Loss Drug Trials To Those At Risk, Not Just Overweight
Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments
Eli Lilly Pumps $800M Into Irish Operations To Meet Skyrocketing Demand For Mounjaro, Zepbound

Mounjaro Recent News

Eli Lilly's Mounjaro Outpaces Novo Nordisk's Ozempic In Weight Loss Effectiveness, Study Shows
Eli Lilly and Co has emerged victorious in the weight loss drug competition, in a recent study. The study found that patients on Lilly's Mounjaro lost more weight than those on Novo Nordisk's Ozempic.
Eli Lilly Expands Fight Against Counterfeit Obesity Drug Zepbound With New Legal Actions
Eli Lilly & Co has intensified its fight against counterfeit versions of its popular obesity drug, Zepbound, by initiating additional legal proceedings against companies selling compounded versions of the medication.
'Not Just A Weight Loss Story:' Eli Lilly CEO Thinks It's Possible To Meet BofA's $60B Revenue Projection From New Drug Launches
Ricks highlighted that the company is trying to prove the efficacy of its drugs for not only weight loss but also obesity-driven diseases such as heart risks, diabetes, and sleep apnea.
South Park Took On Crypto, AI Previously: Animated Comedy Targets Weight-Loss Drug Ozempic Next
Weight loss drugs get the new parody treatment in a "South Park" streaming special.
EXCLUSIVE: GameStop, AMC Buzz 'May Prove To Be Short-Lived,' CEO Of Company Behind MEME ETF Tells Benzinga
The company behind the MEME ETF shares what it would take to bring the meme stock fund back to the market.
Eli Lilly Struggles To Keep Pace With Mounjaro, Zepbound Demand: 'Currently Unavailable' On Amazon Pharmacy
Eli Lilly's stock skyrockets but now trading sideways as demand for weight-loss drugs outpaces supply. Availability issues lead to FDA shortages.
Costco Long Known For Rotisserie Chicken And Hot Dogs Counters Junk Food With Weight Loss Plan To Help You Shed Those Extras
Costco's new weight loss initiative, in partnership with Sesame, a healthcare marketplace, will offer members a three-month clinical consultation and other services for $179.
Is Eli Lilly Winning The War On Weight Loss Drugs? Zepbound Overtakes Wegovy In US Prescriptions
Eli Lilly stock is up 32% so far in 2024 and has risen 318% over three years.
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors
Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher.
Jim Cramer Warns Weight Loss Drugs Ozempic, Wegovy And Others Could Impact Food Stocks: 'That Day Will Come'
Jim Cramer, the host of CNBC's "Mad Money," has issued a warning to investors about the potential impact of weight loss drugs on the food and beverage industry.
Is Tesla Still A Magnificent 7 Stock? EV Maker Could Get Bumped By These Companies
Tesla, relegated from seventh to ninth on the mega-cap leaderboard, can give way to other companies that are more 'magnificent.'
Eli Lilly Soars On Diabetes And Obesity Drug Boom, Projects 20% Revenue Increase In 2024
This surge is attributed to the popularity of Lilly's new diabetes drug, Mounjaro, and its anti-obesity medication, Zepbound.
Take Your Ozempic: Why Late Entry Of Rival Weight-Loss Drugs Won't Floor Novo, Eli Shares
Eli Lilly to report strong Q4 earnings thanks to successful diabetes treatments, while rivals like Novo Nordisk and Pfizer are also vying for a share of the weight-loss market.
Tesla's Market Cap Dips Below Eli Lilly Following Q4 Revenue Miss
Inflation-Busting Price Hikes For Ozempic, Mounjaro And Others: Are Drugmakers Profiteering?
Pharmaceuticals prices are already up in 2024: Can inflation-beating hikes be justified?
Bernie Sanders To Take On Ozempic, Wegovy, Weight Loss Drugs: 'Could Be Helpful, But They're Not Going To Be Helpful If People Can't Afford Them'
A hearing from the Senate led by Bernie Sanders will look at diabetes and the rise of weight loss drugs.
Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
Weight-loss drugs such as Ozempic and Mounjaro are the leading blockbusters for a new epidemic
Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF?
New class of weight-reducing drugs underpin launch of exchange-traded fundTema launches healthcare ETF focused on companies researching and treating cardiovascular disease, obesity and diabetes, including Novo Nordisk's Ozempic.
Weight Loss Drugs Wegovy, Ozempic Gain Traction With Millennials, High Earners: New Survey Results
A new survey reveals the consumer segments showing the greatest interest in weight loss medications such as Ozempic, Mounjaro, and Wegovy.
Eli Lilly To Fly Higher? Fund Manager Gary Black Envisions Blockbuster Potential For Diabetes Drug Mounjaro
Lilly stock has been on a tear this year, thanks to the huge potential its GLP-1 agonist Mounjaro promises.
Eli Lilly's Stock Spikes, Yet Team Jim Cramer Holds Back On Recommending Immediate Buying: 'Wait For A Pullback'
After This Pharma Stock Surges To Record High, Cramer Says It's 'Going Higher Still'
Eli Lilly reported a beat-and-raise Q2 on Tuesday and its stock moving into record territory and Cramer thinks there is more upside to it.
140,000 American Lives At Risk -- And This Drug Could Save Them
A new study could save hundreds of thousands of lives in the United States each year.

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2024 Benzinga | All Rights Reserved